Oakbrook Investments LLC Has $2.17 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Oakbrook Investments LLC grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,888 shares of the company’s stock after purchasing an additional 1,000 shares during the period. Oakbrook Investments LLC’s holdings in IDEXX Laboratories were worth $2,172,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of IDXX. Dimensional Fund Advisors LP raised its holdings in IDEXX Laboratories by 2.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 333,359 shares of the company’s stock worth $62,014,000 after purchasing an additional 7,745 shares during the period. Geode Capital Management LLC raised its holdings in IDEXX Laboratories by 7.6% in the 4th quarter. Geode Capital Management LLC now owns 1,162,909 shares of the company’s stock worth $215,959,000 after purchasing an additional 81,641 shares during the period. MML Investors Services LLC raised its holdings in IDEXX Laboratories by 16.3% in the 4th quarter. MML Investors Services LLC now owns 1,698 shares of the company’s stock worth $316,000 after purchasing an additional 238 shares during the period. Gotham Asset Management LLC acquired a new position in IDEXX Laboratories in the 4th quarter worth about $1,007,000. Finally, Amundi Pioneer Asset Management Inc. raised its holdings in IDEXX Laboratories by 37.2% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 76,385 shares of the company’s stock worth $14,207,000 after purchasing an additional 20,724 shares during the period. Institutional investors own 87.81% of the company’s stock.

In other IDEXX Laboratories news, insider Giovani Twigge sold 2,600 shares of the stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $250.14, for a total transaction of $650,364.00. Following the completion of the transaction, the insider now owns 12,595 shares of the company’s stock, valued at $3,150,513.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Rebecca M. Henderson sold 8,790 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $241.57, for a total value of $2,123,400.30. Following the transaction, the director now directly owns 27,486 shares of the company’s stock, valued at approximately $6,639,793.02. The disclosure for this sale can be found here. Insiders have sold 50,721 shares of company stock valued at $12,554,774 in the last three months. Insiders own 2.70% of the company’s stock.

A number of equities analysts recently weighed in on IDXX shares. Stifel Nicolaus cut Viveve Medical from a “buy” rating to a “hold” rating and reduced their price target for the stock from $3.00 to $1.00 in a report on Monday. Guggenheim reaffirmed a “buy” rating and issued a $95.00 price target (up previously from $90.00) on shares of VF in a report on Thursday, May 23rd. Zacks Investment Research cut Inflarx from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Canaccord Genuity reaffirmed a “speculative buy” rating and issued a GBX 70 ($0.91) price target on shares of Bacanora Lithium in a report on Monday, July 1st. Finally, Bank of America set a $300.00 price target on IDEXX Laboratories and gave the stock a “buy” rating in a report on Friday, June 21st. Eight investment analysts have rated the stock with a buy rating, IDEXX Laboratories presently has an average rating of “Buy” and a consensus price target of $273.86.

Shares of IDEXX Laboratories stock traded up $0.38 during mid-day trading on Friday, reaching $283.94. 183,277 shares of the stock traded hands, compared to its average volume of 334,359. The company has a 50-day moving average price of $276.20. IDEXX Laboratories, Inc. has a fifty-two week low of $176.11 and a fifty-two week high of $292.17. The stock has a market capitalization of $24.40 billion, a PE ratio of 66.65 and a beta of 0.86. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, May 1st. The company reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $1.04 by $0.13. IDEXX Laboratories had a negative return on equity of 1,501.94% and a net margin of 17.33%. The business had revenue of $576.06 million during the quarter, compared to analysts’ expectations of $575.04 million. During the same quarter in the prior year, the firm earned $1.01 earnings per share. The business’s revenue was up 7.1% compared to the same quarter last year. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 4.82 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Article: Using other technical indicators with support levels

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.